Lupin gets approval for atorvastatin calcium tablets

Lupin has received approval for its Atorvastatin Calcium Tablets from the US drug regulator.

The United States Food and Drug Administration (USFDA) has given their approval for USP, 10 mg, 20 mg, 40 mg, and 80 mg to Lupin to market the tablets in the US.

Lupin's Atorvastatin Calcium Tablets, is the generic version of Pfizer Inc's Lipitor Tablets, 10 mg, 20 mg, 40 mg and 80 mg. It is indicated to lower cholesterol levels in blood for adults and children aged over 10 years. Atorvastatin is also prescribed to lower the risk for heart attack, stroke in patients with cardiovascular diseases. It also works to lower the risk of diabetes and other risk factors such as eye problems, kidney diseases or high BP.

Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg reported annual sales of approximately US$696 million in the US.

Lupin is involved in developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

The shares of Lupin on Friday opened at Rs. 799.80 per share against Thursday’s close of Rs. 791. At  hours, the shares were trading at Rs 790.05, down by 0.13 per cent. The stock hit an intraday high of Rs. 799.80 and an intraday low of Rs. 789.75 per share on the BSE. The 52-week high stood at Rs. 986 and the 52-week low was Rs 723.55 per share on the BSE.

Meanwhile, Sensex was quoting 36,636.96 level, down by 0.30 per cent